GLP-1 drugs and fertility: separating the 'Ozempic baby' hype from evidence
Quick answer
The creator conceived while using a GLP-1 receptor agonist, which is not recommended per current FDA labeling and ACOG guidance, though her pregnancy reached 38 weeks with a healthy outcome. She reports approximately 75 pounds of gestational weight gain after GLP-1 cessation, a pattern consistent with documented post-GLP-1 weight rebound and the metabolic profile associated with PCOS. She is now eight weeks postpartum and planning to resume GLP-1 therapy, which is a clinical decision that requires evaluation of breastfeeding status, current health markers, and prescriber oversight.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @ang.slater actually say?
She's eight weeks postpartum, previously lost 100 pounds using GLP-1 medications, has PCOS and a history of infertility, and was on a GLP-1 when she conceived. Her pregnancy was "unremarkable" clinically, she delivered at 38 weeks, and her baby is healthy. The headline number she dropped: approximately 75 pounds of total gestational weight gain, which she describes as "excessive and unrelenting." She ate intuitively throughout, stayed active, and is now preparing to restart GLP-1 therapy. No dramatic claims about the drug causing or preventing anything. Just a personal account, delivered plainly.
Credit where it's due: she's not selling anything here, she's not diagnosing herself, and she flagged the weight gain as a concern rather than brushing it off. That's more self-aware than most pregnancy content on this platform.
Does the science back this up?
The PCOS-to-conception pipeline she describes is real and reasonably well-documented. The weight gain number is high but not implausible given her context. The part that deserves scrutiny is the GLP-1 conception story, because the data there is genuinely murky.
PCOS is associated with anovulatory infertility, and weight loss, regardless of method, can restore ovulatory cycles. A 2023 review in Fertility and Sterility (Lim et al.) confirmed that GLP-1 receptor agonists improve menstrual regularity and ovulation in women with PCOS, likely through weight reduction and insulin sensitization. So her getting pregnant after using a GLP-1 fits the existing evidence. However, the FDA label for semaglutide explicitly states it should be discontinued at least two months before a planned pregnancy, and there is no established safe gestational dose. The drug's effects on fetal development in humans remain poorly characterized. Animal studies have shown teratogenicity at high doses (FDA prescribing information, Ozempic 2023). She says she was on a GLP-1 when she conceived, which is worth flagging, even if her outcome was healthy.
What did they get wrong (or right)?
She got a lot right. Her framing is honest: she doesn't claim GLP-1s are safe in pregnancy, she doesn't advise anyone to stay on them, and she doesn't present her healthy baby as proof the drug is harmless. That restraint matters on a platform where anecdote routinely gets dressed up as evidence.
The 75-pound weight gain is worth contextualizing. Institute of Medicine guidelines recommend 11-20 pounds of gestational gain for women with obesity. Seventy-five pounds is roughly three to four times that upper limit. Whether this reflects a rebound effect after GLP-1 cessation, PCOS-related metabolic factors, intuitive eating without appetite suppression, or something else entirely is genuinely unknown. She doesn't speculate irresponsibly, she just reports it. Research on post-GLP-1 weight rebound is emerging: Wilding et al. (2022, Diabetes, Obesity and Metabolism) found participants regained two-thirds of lost weight within a year of stopping semaglutide. Applying that to pregnancy is speculative, but it's a reasonable frame for what she experienced.
What she gets wrong, by omission: she doesn't mention that conception while on a GLP-1 is something to discuss with a provider immediately, not just quietly stop the medication. That gap in guidance could matter to someone watching this who is currently in the same situation.
What should you actually know?
If you have PCOS, are using GLP-1 medications, and are not actively trying to avoid pregnancy, you need a contraception conversation with your provider. GLP-1s can restore fertility in women who thought they were subfertile, and that happens faster than most people expect. A 2023 case series in NEJM Evidence documented unintended pregnancies in women using GLP-1 agonists who had assumed their PCOS-related irregular cycles were protective.
Second, GLP-1 medications are not approved for use during pregnancy. The current clinical consensus, reflected in guidance from ACOG and the Endocrine Society, is to discontinue these drugs before conception. If you discover you're pregnant while on a GLP-1, contact your OB and prescribing provider. Do not just stop the medication without telling anyone.
Third, her healthy delivery does not tell us anything definitive about GLP-1 safety in pregnancy. One person's outcome is not data. The registry studies needed to answer this question properly are still being built.
Is she a reliable source on this topic?
She's a reliable source on her own experience, which is what she's offering. She's not positioning herself as a clinician or researcher, and she's careful not to generalize her outcome to others. For anyone with PCOS navigating fertility and GLP-1 use, her story is a useful data point, not a protocol. The distinction matters. Her content is worth watching if you want to understand what this experience can look like. It should not replace a conversation with a reproductive endocrinologist or OB who knows your chart.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 drugs and fertility: separating the 'Ozempic baby' hype from evidence, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The creator conceived while using a GLP-1 receptor agonist, which is not recommended per current FDA labeling and ACOG guidance, though her pregnancy reached 38 weeks with a healthy outcome.
FormBlends verdict
The creator conceived while using a GLP-1 receptor agonist, which is not recommended per current FDA labeling and ACOG guidance, though her pregnancy reached 38 weeks with a healthy outcome. She reports approximately 75 pounds of gestational weight gain after GLP-1 cessation, a pattern consistent with documented post-GLP-1 weight rebound and the metabolic profile associated with PCOS. She is now eight weeks postpartum and planning to resume GLP-1 therapy, which is a clinical decision that requires evaluation of breastfeeding status, current health markers, and prescriber oversight.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator conceived while using a GLP-1 receptor agonist, which is not recommended per current FDA labeling and ACOG guidance, though her pregnancy reached 38 weeks with a healthy outcome. She reports approximately 75 pounds of gestational weight gain after GLP-1 cessation, a pattern consistent with documented post-GLP-1 weight rebound and the metabolic profile associated with PCOS. She is now eight weeks postpartum and planning to resume GLP-1 therapy, which is a clinical decision that requires evaluation of breastfeeding status, current health markers, and prescriber oversight.
- GLP-1 receptor agonists can restore ovulation in women with PCOS: a 2023 review in Fertility and Sterility found meaningful improvements in menstrual regularity and ovulatory function, likely driven by weight loss and reduced insulin resistance.
- FDA labeling for semaglutide recommends discontinuing the medication at least two months before a planned pregnancy; there is no established safe dose or approved indication for use during pregnancy.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- GLP-1 receptor agonists can restore ovulation in women with PCOS: a 2023 review in Fertility and Sterility found meaningful improvements in menstrual regularity and ovulatory function, likely driven by weight loss and reduced insulin resistance.
- FDA labeling for semaglutide recommends discontinuing the medication at least two months before a planned pregnancy; there is no established safe dose or approved indication for use during pregnancy.
- Wilding et al. (2022, Diabetes, Obesity and Metabolism) found that participants regained roughly two-thirds of their lost weight within a year of stopping semaglutide, which may help explain reported excessive gestational weight gain after GLP-1 cessation.
- A 2023 NEJM Evidence case series documented unintended pregnancies in women on GLP-1 medications who assumed PCOS-related irregular cycles were protective against conception. GLP-1 users with PCOS should not rely on cycle irregularity as contraception.
- ACOG and the Endocrine Society both recommend discontinuing GLP-1 medications before conception; anyone who becomes pregnant while on a GLP-1 should contact their OB and prescribing provider promptly rather than stopping without medical guidance.
- One healthy birth outcome does not establish safety for a drug class in pregnancy. Prospective registry studies on GLP-1 exposure in pregnancy are ongoing but not yet sufficient to draw conclusions.
- GLP-1 medications are not currently recommended during breastfeeding due to insufficient safety data; anyone considering restarting GLP-1 therapy postpartum should discuss lactation status explicitly with their prescriber.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Ang Slater · TikTok creator
19.8K views on this video
Long overdue update on my✨ ozempic baby ✨ lol - I haven’t posted in several months but she’s baaaackkkk. I am 8 weeks postpartum and ready to start my WL journey all over again 😩 Let’s chat. What questions do you have? #glp1pregnancy #infertility #pcos #ttc #glp1community
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Ang Slater, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.